Memo Therapeutics creates unique antibody libraries that represent an individual’s immune repertoire, which can be used for antibody discovery and target discovery for antibody and vaccine development. Their platforms, MemoMAB™ and DROPZYLLA™, are deployed in proprietary antibody discovery programs and collaborations, providing new possibilities in immune repertoire analysis and antibody discovery.